Drug
Hydrochlorothiazide 25 mg
Hydrochlorothiazide 25 mg is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
4
67%
Ph phase_3
1
17%
Ph phase_1
1
17%
Phase Distribution
1
Early Stage
0
Mid Stage
5
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
4(66.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(2)
Terminated(2)
Other(1)
Detailed Status
Withdrawn2
Completed2
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (16.7%)
Phase 31 (16.7%)
Phase 44 (66.7%)
Trials by Status
withdrawn233%
recruiting117%
completed233%
unknown117%
Recent Activity
1 active trials
Showing 5 of 6
recruitingphase_3
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264
withdrawnphase_4
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
NCT03423355
completedphase_1
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
NCT03971929
completedphase_4
Empagliflozin and Sympathetic Nerve Traffic
NCT03254849
unknownphase_4
Chlorthalidone and HCTZ Impacts on Platelet Activation
NCT02100462
Clinical Trials (6)
Showing 6 of 6 trials
NCT05373264Phase 3
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT03423355Phase 4
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
NCT03971929Phase 1
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
NCT03254849Phase 4
Empagliflozin and Sympathetic Nerve Traffic
NCT02100462Phase 4
Chlorthalidone and HCTZ Impacts on Platelet Activation
NCT01822860Phase 4
Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6